Trial Profile
A study evaluating predictive role of longitudinal MRI scans for tau positivity in patients with Alzheimer's disease.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Aug 2017
Price :
$35
*
At a glance
- Drugs Florbetapir F 18 (Primary) ; Flortaucipir-F-18 (Primary)
- Indications Alzheimer's disease
- Focus Diagnostic use
- 24 Aug 2017 New trial record
- 20 Jul 2017 Results presented at the Alzheimer's Association International Conference 2017